Download PDF
Open Access
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2007; 28(01): 5-6
DOI: 10.1055/s-0041-1733196
Editorial

Imatinib Mesylate in Chronic Myeloid Leukemia

Authors

  • Pravas Mishra

    Department of Hematology, All India Institute of Medical Sciences, New Delhi, India
Further Information
Also available at
 PDF Download Permissions and Reprints
Preview Container


Publication History

Article published online:
23 March 2022

© 2007. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-20
  • 2 Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.
  • 3 Arora B, Kumar L, Kumari M, et al: Therapy with imatinib mesylate for chronic myeloid leukemia. Ind Jn Med & Paed Oncology 2005;26:5-16.
  • 4 Desmukh C, Saikia T, Bakshi A, et al: Imatinib mesylate in chronic myeloid leukemia: A prospective, single arm, non-randomised study. JAPI 2005;53:291-295.
  • 5 Jacob LA, Bapsy PP, Babu KG, and Loknath Imatinib mesylate in newly diagnosed patients of chronic phase, chronic myeloid leukemia Ind J. Med & Paed Oncol 2007;28.
  • 6 Hughes T. ABL Kinase inhibitor therapy for CML: Baseline Assessments and response monitoring. Hematology (Am Soc Hematol Edu Program). 2006:211-218.